Bernard S Kadosh, Antoinette S Birs, Erin Flattery, Maxine Stachel, Kimberly N Hong, Yuhe Xia, Claudia Gidea, Saima Aslam, Louai Razzouk, Tajinderpal Saraon, Randal Goldberg, Shaline Rao, Victor Pretorius, Nader Moazami, Deane E Smith, Eric D Adler, Alex Reyentovich
BACKGROUND: Recent studies suggest the transplantation of Hepatitis C (HCV) hearts from viremic donors is associated with comparable 1 year survival to nonviremic donors. Though HCV viremia is a known risk factor for accelerated atherosclerosis, data on cardiac allograft vasculopathy (CAV) outcomes are limited. We compared the incidence of CAV in heart transplant recipients from HCV viremic donors (nucleic acid amplification test positive; NAT+) compared to non-HCV infected donors (NAT-)...
April 2024: Clinical Transplantation